5.0, or 10.0 mg PO daily. The primary outcome of interest is a
composite end-point of cardiac death or HF hospitalization.
Although our understanding of the genetics and etiology of
HF has improved in the last two decades, the prognosis of
patients diagnosed with HF has not changed appreciably.
Amongst the newly established therapies, SGLT-2 inhibitors
offer the promise of additional medical therapy that can be
applied to a general HF population with moderate to severe
left ventricular systolic dysfunction. Interventional therapies
such as the mitral valve clip and AF ablation may improve
important patient related outcomes; however, their applicability
is limited to highly selected patient populations. None of
these therapies have been strongly recommended by current
practice guidelines, but it is expected that this may change in
their next iteration. The ongoing large-scale studies of OM
and vericiguat outlined above offer the promise of improving
outcomes in patients with HF.
1. Savarese G and Lund LH. Global public health burden of heart failure.
Cardiac Failure Rev 2017;3:7.
2. Taylor JM, Ordóñez-Mena AK, Roalfe S, et al. Trends in survival after a
diagnosis of heart failure in the United Kingdom 2000-2017: population
based cohort study. BMJ 2019;364:l223.
3. Ezekowitz JA, O’Meara E, McDonald MA, et al. 2017 Comprehensive Update
of the Canadian Cardiovascular Society Guidelines for the Management of
Heart Failure. Can J Cardiol 2017;33:1342–33.
4. Ponikowski P, Voors, SD, AA, Anker H, et al. 2016 ESC Guidelines for
the diagnosis and treatment of acute and chronic heart failure: The Task
Force for the diagnosis and treatment of acute and chronic heart failure
of the European Society of Cardiology (ESC). Developed with the special
contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart
5. Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with
weight loss, lower insulin doses, and no increased hypoglycemia with
empagliflozin added to titrated multiple daily injections of insulin in obese
inadequately controlled type 2 diabetes. Diabet Care 2014;37:1815–23.
6. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared
with sitagliptin for patients with type 2 diabetes who do not have adequate
glycemic control with metformin plus sulfonylurea: a 52-week randomized
trial. Diabet Care 2013;36:2508–15.
7. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and
renal events in type 2 diabetes. New Engl J Med 2017;377:644–57.
8. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and
secondary prevention of cardiovascular and renal outcomes in type 2
diabetes: a systematic review and meta-analysis of cardiovascular outcome
trials. Lancet 2019;393:31–39.
9. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular
outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–28.
10. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular
outcomes in type 2 diabetes. N Engl J Med 2019;380:347–57.
11. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in
patients with heart failure and reduced ejection fraction. N Engl J Med
12. Cherney DZ, Odutayo A, Aronson R, et al. Sodium Glucose Cotransporter-2
Inhibition and Cardiorenal Protection: JACC Review Topic of the Week. J
Am Coll Cardiol 2019;74:2511–24.
13. Asgar AW, Mack MJ, and Stone GW. Secondary mitral regurgitation in heart
failure: pathophysiology, prognosis, and therapeutic considerations. J Am
Coll Cardiol 2015;65:1231–48.
14. Sannino A, Smith RL, Schiattarella GG, et al. Survival and cardiovascular
outcomes of patients with secondary mitral regurgitation: a systematic review
and meta-analysis. JAMA Cardiol 2017;2:1130–39.
15. Goliasch G, Bartko PE, Pavo N, et al. Refining the prognostic impact
of functional mitral regurgitation in chronic heart failure. Eur Heart J
16. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused
update of the 2014 AHA/ACC guideline for the management of patients
with valvular heart disease: a report of the American College of Cardiology/
American Heart Association Task Force on Clinical Practice Guidelines. J
Am Coll Cardiol 2017;70:252–89.
17. Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve
repair in patients with heart failure. N Engl J Med 2018;379:2307–18.
18. Obadia J-F, Messika-Zeitoun D, Leurent G, et al. Percutaneous repair
or medical treatment for secondary mitral regurgitation. N Engl J Med
19. Atianzar K, Zhang M, Newhart Z, and Gafoor S. Why did COAPT win while
MITRA-FR failed? defining the appropriate patient population for MitraClip.
Intervent Cardiol (London, England) 2019;14:45–47.
20. Cha Y-M, Redfield MM, Shen W-K, and Gersh BJ. Atrial fibrillation and
ventricular dysfunction: a vicious electromechanical cycle. Circulation
21. Santhanakrishnan R, Wang N, Larson MG, et al. Atrial fibrillation begets
heart failure and vice versa: temporal associations and differences in
preserved versus reduced ejection fraction. Circulation 2016;133:484–92.
22. Mamas MA, Caldwell JC, Chacko S, et al. A meta-analysis of the prognostic
significance of atrial fibrillation in chronic heart failure. Eur J Heart Failure
23. Skanes AC, Healey JS, Cairns JA, et al. Focused 2012 Update of
the Canadian Cardiovascular Society Atrial Fibrillation Guidelines:
Recommendations for Stroke Prevention and Rate/Rhythm Control. Can J
24. Turagam MK, Garg J, Whang W, et al. Catheter ablation of atrial fibrillation
in patients with heart failure: a meta-analysis of randomized controlled trials.
Ann Intern Med 2019;170:41–50.
25. Packer DL, Mark DB, Robb RA, et al. Effect of catheter ablation vs
antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest
among patients with atrial fibrillation: The CABANA Randomized Clinical
Trial. JAMA 2019;321:1261–74.
26. Aljundi AHS, Mohammed SFK, Patel A, et al. Inotropic agents use in
patients hospitalized with acute decompensated heart failure: a retrospective
analysis from a 22-year registry in a Middle-Eastern Country (1991--2013).
BMC Cardiovasc Disord 2016;16:47.
27. Tariq S and Aronow WS. Use of inotropic agents in treatment of systolic heart
failure. Internat J Molec Sci 2015;16:29060–9068.
28. Teerlink JR, Felker GM, McMurray JJ, et al. Honarpour N; COSMIC-HF
investigators. Chronic oral study of myosin activation to increase contractility
in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised,
placebo-controlled trial. Lancet 2016;388:2895–903.
29. Greenberg B. Novel therapies for heart failure--where do they stand?
Circulation J 2016;16.
30. Teerlink JR, Felker GM, McMurray JJV, et al. Acute treatment with
omecamtiv mecarbil to increase contractility in acute heart failure: the
ATOMIC-AHF study. J Am Coll Cardiol 2016;67:1444–55.
31. Planelles-Herrero VJ, Hartman JJ, Robert-Paganin, et al. Mechanistic
and structural basis for activation of cardiac myosin force production by
omecamtiv mecarbil. Nature Communicat 2017;8:190.
Canadian Journal of General Internal Medicine
26 Volume 15, Special Issue 1, 2020
Heart Failure Special Issue
(Continued on page 35)
CJGIM_15_Special_Issue_174016.indd 26CJGIM_15_Special_Issue_174016.indd 26 04/04/20 8:35 PM04/04/20 8:35 PM